SLP (Simulations Plus) 3-Year RORE % : 140.23% (As of Feb. 2026)


SLP Simulations Plus Inc SLP
81 GF Score
Price $18.38
GF Value $38.31
Valuation Significantly Undervalued
! 7 Warning Signs
View Full Analysis

What is Simulations Plus 3-Year RORE %?

Simulations Plus SLP +0.22% 81 3-Year RORE % is 140.23 as of Feb. 2026. GuruFocus rates SLP with a GF Score™ of 81/100 and a GF Value™ of $38.31 (Significantly Undervalued). The stock has 7 warning signs investors should review. Among 605 Healthcare Providers & Services companies, Simulations Plus ranks better than 93.72% on this metric.

Return on Retained Earnings (RORE) is an indicator of a company's growth potential, it shows how much a company earns by reinvesting its retained earnings, i.e. profits after dividend payments. Simulations Plus's 3-Year RORE % for the quarter that ended in Feb. 2026 was 140.23%.

The industry rank for Simulations Plus's 3-Year RORE % or its related term are showing as below:

SLP's 3-Year RORE % is ranked better than
93.72% of 605 companies
in the Healthcare Providers & Services industry
Industry Median: 0.07 vs SLP: 140.23

Simulations Plus  (NAS:SLP) 3-Year RORE % Explanation

Return on Retained Earnings (RORE) is important to investors because it reveals a company's efficiency and growth potential. A higher RORE indicates a higher return. A high RORE indicates that the company should reinvest profits into the business. A lower RORE suggests that the company should distribute profits to shareholders by paying out dividends, since those dollars aren't generating much additional growth for the company.

There are a several different ways to arrive at the Return on Retained Earnings. The simplest way to calculate it is by using published information on Earnings per Share (EPS) and Dividend per Share (DPS) over a selected period. Here, 3-year period is chosen.

Be Aware

Please keep in mind that the RORE is relative to the nature of the business and its competitors. If another company in the same sector is producing a lower return on retained earnings, it doesn’t necessarily mean it’s a bad investment. It may just suggest the company is older and no longer in a high growth stage. At such a stage in the business cycle, it would be expected to see a lower RORE and higher dividend payout.


Simulations Plus 3-Year RORE % Related Terms


Simulations Plus 3-Year RORE % Historical Data

* Premium members only.

The historical data trend for Simulations Plus's 3-Year RORE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Simulations Plus 3-Year RORE % Chart

Simulations Plus Annual Data
Trend Aug16 Aug17 Aug18 Aug19 Aug20 Aug21 Aug22 Aug23 Aug24 Aug25
3-Year RORE %
Get a 7-Day Free Trial Premium Member Only Premium Member Only -2.78 11.90 3.61 -12.79 136.40

Simulations Plus Quarterly Data
May21 Aug21 Nov21 Feb22 May22 Aug22 Nov22 Feb23 May23 Aug23 Nov23 Feb24 May24 Aug24 Nov24 Feb25 May25 Aug25 Nov25 Feb26
3-Year RORE % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -19.23 134.69 136.40 138.66 140.23

SLP vs TBRG, CARL, NRC: 3-Year RORE % Comparison

For the Health Information Services subindustry, Simulations Plus's 3-Year RORE %, along with its competitors' market caps and 3-Year RORE % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Simulations Plus 3-Year RORE % vs Healthcare Providers & Services Industry

For the Healthcare Providers & Services industry and Healthcare sector, Simulations Plus's 3-Year RORE % distribution charts can be found below:

* The bar in red indicates where Simulations Plus's 3-Year RORE % falls into.


SLP
81GF Score
Simulations Plus Inc SLP
3-Year RORE % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Simulations Plus 3-Year RORE % Calculation

Simulations Plus's 3-Year RORE % for the quarter that ended in Feb. 2026 is calculated as:

3-Year RORE %=( Most Recent EPS (Diluted)- First Period EPS (Diluted) )/( Cumulative EPS (Diluted) for 3-year -Cumulative Dividends per Share for 3-year )
=( -3.13-0.53 )/( -2.25-0.36 )
=-3.66/-2.61
=140.23 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of 3-Year RORE %, the most recent and first period EPS (Diluted) is the trailing twelve months (TTM) data ended in Feb. 2026 and 3-year before.

Frequently Asked Questions Learn more about 3-Year RORE % →
What does a 3-Year RORE % of 140.23 mean?
Simulations Plus (SLP) has a 3-Year RORE % of 140.23 as of Feb. 2026. 3-Year RORE % shows how much a company earns by reinvesting its retained earnings in 3-year. View historical data on Simulations Plus and its competitors. According to the industry distribution chart, Simulations Plus ranks #38 out of 605 companies in the Healthcare Providers & Services industry, placing it in the top 6.3%.
Is Simulations Plus' 3-Year RORE % too high?
Simulations Plus' current 3-Year RORE % is 140.23. The Healthcare Providers & Services industry median 3-Year RORE % is 0.07. Simulations Plus' value of 140.23 is 200228.6% above this industry median. Based on the distribution chart, Simulations Plus ranks #38 out of 605 companies in the Healthcare Providers & Services industry, which is in the top quartile — a strong position relative to peers. Overall, Simulations Plus has a GF Score™ of 81/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Simulations Plus' 3-Year RORE % compare to TBRG and CARL?
According to the Healthcare Providers & Services industry distribution chart, Simulations Plus ranks #38 out of 605 companies for 3-Year RORE %. This places Simulations Plus in the top 6% of its industry — outperforming the majority of peers. The industry median 3-Year RORE % is 0.07. Simulations Plus' value of 140.23 is 200228.6% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year RORE % for a Healthcare Providers & Services company?
The median 3-Year RORE % among Healthcare Providers & Services companies is 0.07, based on 605 companies in the industry. Companies in the top quartile (top 25%) have a 3-Year RORE % significantly above this median, while those in the bottom quartile fall well below. However, 3-Year RORE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Simulations Plus's current 3-Year RORE % of 140.23 is 200228.6% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year RORE % mean?
A high 3-Year RORE % can signal that a stock is expensive relative to its fundamentals. 3-Year RORE % shows how much a company earns by reinvesting its retained earnings in 3-year. View historical data on Simulations Plus and its competitors. For the Healthcare Providers & Services industry, the median 3-Year RORE % is 0.07 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Simulations Plus's current 3-Year RORE % is 140.23. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Simulations Plus stock overvalued right now?
Based on GuruFocus' analysis, Simulations Plus (SLP) is currently considered Significantly Undervalued. The stock's GF Value™ is $38.31, compared to a current price of $18.38 — trading 52% below its estimated fair value. The current 3-Year RORE % is 140.23 and 200228.6% above the Healthcare Providers & Services industry median of 0.07. Simulations Plus' overall GF Score™ is 81/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year RORE % calculated?
3-Year RORE % is calculated from a company's financial statements. For Simulations Plus (SLP), the current 3-Year RORE % is 140.23 as of Feb. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Simulations Plus (SLP) Overvalued in 2026?

Based on GuruFocus' analysis, Simulations Plus stock appears to be undervalued. The current stock price of $18.38 is trading 52% below its estimated GF Value™ of $38.31. GuruFocus considers Simulations Plus to be Significantly Undervalued.

Key valuation signals for SLP:

  • 3-Year RORE %: 140.23
  • GF Value™: $38.31 vs. price of $18.38 (52% below fair value)
  • GF Score™: 81/100 with 7 warning signs
  • Industry Position: 200228.6% above the Healthcare Providers & Services median (#38 of 605)

No single metric tells the full story. See the SLP stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Simulations Plus Business Description

Other Exchanges SD3:Germany
Address 800 Park Offices Drive, Suite 401, Research Triangle Park, Lancaster, NC, USA, 27709
Simulations Plus Inc is engaged in the software industry. It develops and produces software for use in pharmaceutical research and education, and provides consulting and contract research services to the pharmaceutical industry. The company's operating segments include Software and services. The company offers software products for pharmaceutical research such as ADMET (Absorption, Distribution, Metabolism, Excretion, and Toxicity). It generates maximum revenue from the software segment. Maximum revenue is earned from USA following EMEA and Asia Pacific.
81GF Score

Get the complete analysis for SLP

3-Year RORE % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$18.38
Price
$38.31
GF Value